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Renal cell carcinoma accounts for approximately 2--5% of adult malignancies worldwide, and approximately 350 000 new cases are diagnosed, with over 140 000 deaths, each year.[1](#cas13331-bib-0001){ref-type="ref"}, [2](#cas13331-bib-0002){ref-type="ref"} Most cases of RCC (approximately 80%) are classified as ccRCC.[3](#cas13331-bib-0003){ref-type="ref"} In the majority of patients, ccRCC is associated with dysfunction of the *VHL* gene.[4](#cas13331-bib-0004){ref-type="ref"}, [5](#cas13331-bib-0005){ref-type="ref"} Lack of *VHL* function causes activation of HIF and VEGF pathways in ccRCC cells.[6](#cas13331-bib-0006){ref-type="ref"}, [7](#cas13331-bib-0007){ref-type="ref"} The mTOR pathway is also activated by dysregulation of HIF and VEGF pathways in patients with ccRCC.[8](#cas13331-bib-0008){ref-type="ref"}, [9](#cas13331-bib-0009){ref-type="ref"}

Based on this information regarding the molecular pathogenesis of ccRCC, molecular targeted therapies for patients with advanced and metastatic RCC have been developed during the past decade.[10](#cas13331-bib-0010){ref-type="ref"} The molecular‐targeted agents sorafenib, sunitinib, pazopanib, axitinib, bevacizumab, and cabozantinib inhibit VEGF and VEGF receptor pathways, and temsirolimus and everolimus inhibit the mTOR pathway; treatment with these agents has resulted in significant benefits to patients with advanced RCC.[10](#cas13331-bib-0010){ref-type="ref"}, [11](#cas13331-bib-0011){ref-type="ref"} However, the curative effects of these treatments are limited because cancer cells exhibit activation of several alternative signal cascades and acquire resistance to these treatments during therapeutic processes.[11](#cas13331-bib-0011){ref-type="ref"}, [12](#cas13331-bib-0012){ref-type="ref"} Treatment strategies for drug‐resistant cancer cells are limited, and the prognosis of these patients is extremely poor. However, the molecular mechanisms of resistance to molecular‐targeted therapies in RCC cells are still unclear.

miRNAs act as pivotal players that regulate the expression control of protein‐coding/protein‐noncoding RNAs in a sequence‐dependent manner.[13](#cas13331-bib-0013){ref-type="ref"}, [14](#cas13331-bib-0014){ref-type="ref"} Notably, a single miRNA can directly control many mRNAs in human cells.[15](#cas13331-bib-0015){ref-type="ref"} Therefore, aberrantly expressed miRNAs can disrupt the tight control of RNA expression in cancer cells. Moreover, dysregulation of miRNAs is deeply involved in cancer cell progression, metastasis, and drug resistance.[16](#cas13331-bib-0016){ref-type="ref"}, [17](#cas13331-bib-0017){ref-type="ref"}, [18](#cas13331-bib-0018){ref-type="ref"}, [19](#cas13331-bib-0019){ref-type="ref"}

In RCC, miRNAs are closely related to the development of cancer, and previous studies have reported the relationships among many miRNAs and RCC. For example, the *miR‐200* family, containing *miR‐141*,*miR200a/b/c*, and *miR‐429*, forms two clusters, *miR‐200a/200b/429* and *miR‐141/200c*, and expression of the *miR‐200* family is markedly downregulated in RCC tissues.[20](#cas13331-bib-0020){ref-type="ref"} Additionally, the *miR‐200* family has been reported to be involved in the EMT in several cancers, and *miR‐141* and *miR‐200c* function as tumor suppressors in RCC by inhibiting the EMT through targeting of *ZFHX1B*, a transcriptional repressor for CDH1/E‐cadherin.[20](#cas13331-bib-0020){ref-type="ref"}, [21](#cas13331-bib-0021){ref-type="ref"} In this way, investigation of molecular networks based on miRNAs may help to elucidate the molecular mechanisms mediating the progression of RCC.

Analysis of our original miRNA expression signature of TKI failure in patients with RCC showed that antitumor *miR‐101* directly regulated ubiquitin‐like with PHD and ring finger domains 1 (*UHRF1*), which acted as an oncogene in RCC cells.[22](#cas13331-bib-0022){ref-type="ref"} Based on this signature, we focused on *miR‐10a‐5p* because *miR‐10a‐5p* is significantly downregulated in TKI‐treated ccRCC compared with primary ccRCC.[22](#cas13331-bib-0022){ref-type="ref"} Moreover, The Cancer Genome Atlas[23](#cas13331-bib-0023){ref-type="ref"} database showed that the overall survival of patients in the low *miR‐10a‐5p* expression group was significantly shorter than that of patients in the high expression group in ccRCC (*P* = 0.00991, Fig. [1](#cas13331-fig-0001){ref-type="fig"}a).

![Kaplan‐Meier survival curves based on *miR‐10a‐5p* expression in patients with clear cell renal cell carcinoma (ccRCC), and schematic representation of the chromosomal location of human *miR‐10a*. (a) Kaplan‐Meier survival curve for overall survival rate based on *miR‐10a‐5p* expression in patients with ccRCC from The Cancer Genome Atlas (TCGA) database. (b) *miR‐10a* is located on human chromosome 17q21.32. Mature microRNAs (miRNAs), *miR‐10a‐5p* (guide strand) and *miR‐10a‐3p* (passenger strand), are derived from pre‐*miR‐10a*.](CAS-108-2088-g001){#cas13331-fig-0001}

The aims of the present study were to investigate the functional significance of *miR‐10a‐5p* and to identify the molecular targets regulated by *miR‐10a‐5p* in ccRCC cells. Our data showed that restoration of mature *miR‐10a‐5p* inhibited ccRCC cell proliferation, migration, and invasion. Furthermore, our data demonstrated that the *SKA1* gene was overexpressed in primary RCC and advanced RCC specimens and was directly regulated by *miR‐10a‐5p* in RCC cells. These results demonstrated that *SKA1* was involved in RCC pathogenesis, implying that *SKA1* could be a novel diagnostic and therapeutic target for patients with advanced RCC.

Materials and Methods {#cas13331-sec-0002}
=====================

ccRCC clinical specimens and cell culture {#cas13331-sec-0003}
-----------------------------------------

A total of 15 pairs of ccRCC specimens and adjacent noncancerous specimens were collected from patients who had undergone radical nephrectomy at Chiba University Hospital (Chiba, Japan) from 2012 to 2015. Clinicopathological characteristics of the patients are summarized in Table [1](#cas13331-tbl-0001){ref-type="table-wrap"}. Four patients who died of ccRCC after TKI treatment underwent autopsy at Teikyo University Chiba Medical Center Hospital from 2012 to 2016, as summarized in Table [2](#cas13331-tbl-0002){ref-type="table-wrap"}. These specimens were staged according to the General Rule for Clinical and Pathological Studies on Renal Cell Carcinoma based on the American Joint Committee on Cancer (AJCC)‐UICC TNM classification.[24](#cas13331-bib-0024){ref-type="ref"} Written consent for tissue donation for research purposes was obtained from each patient before tissue collection. We used two human ccRCC cell lines (786‐O and A498) obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) as previously described.[22](#cas13331-bib-0022){ref-type="ref"}, [25](#cas13331-bib-0025){ref-type="ref"}, [26](#cas13331-bib-0026){ref-type="ref"}, [27](#cas13331-bib-0027){ref-type="ref"}, [28](#cas13331-bib-0028){ref-type="ref"}

###### 

Characteristics of primary ccRCC clinical specimens

  No.   Age (years)   Sex   Pathology    Grade        pT    INF   v   ly   e.g or ig   fc   im   rc   rp   s
  ----- ------------- ----- ------------ ------------ ----- ----- --- ---- ----------- ---- ---- ---- ---- ---
  1     71            F     Clear cell   G2           T1a   a     0   0    e.g         1    0    0    0    0
  2     74            M     Clear cell   G1\>G2       T1a   a     0   0    e.g         1    0    0    0    0
  3     59            M     Clear cell   G3\>G2       T1b   a     0   0    e.g         1    0    0    0    0
  4     79            M     Clear cell   G2\>G3\>G1   T1a   a     0   0    e.g         1    0    0    0    0
  5     52            M     Clear cell   G2\>G3       T1b   a     0   0    e.g         1    1    0    0    0
  6     64            M     Clear cell   G2\>G3\>G1   T3a   b     1   0    ig          0    1    1    0    0
  7     67            M     Clear cell   G2\>G3\>G1   T3a   b     1   0    ig          1    0    0    0    0
  8     59            M     Clear cell   G3           T3a   b     1   0    ig          0    0    0    0    0
  9     73            M     Clear cell   G1\>\>G3     T2a   a     0   1    e.g         1    0    0    0    0
  10    77            M     Clear cell   G1\>G2       T1b   a     0   0    e.g         1    0    0    0    0
  11    51            F     Clear cell   G2\>G1\>G3   T3a   b     1   0    ig          0    0    0    0    0
  12    84            F     Clear cell   G2           T1a   a     0   0    e.g         0    0    0    0    0
  13    78            M     Clear cell   G2\>G1≫G3    T1b   b     0   0    e.g         1    0    0    0    0
  14    44            M     Clear cell   G2\>G1       T1a   b     0   0    e.g         1    0    0    0    0
  15    57            M     Clear cell   G2           T1b   a     0   0    e.g         0    0    0    0    0

ccRCC, clear cell renal cell carcinoma; e.g, expansive growth; fc, capsular formation; ig, infiltrative growth; im, intrarenal metastasis; INF, infiltration; ly, lymph node; rc, renal capsule invasion; rp, pelvis invasion; s, sinus invasion; v, vein.
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###### 

Characteristics of ccRCC autopsy specimens after TKI treatment

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient   Specimen no.    Location      Age (years)   Stage at diagnosis   Histological type   Grade   Treatment   Treatment duration (months)                        Pathological feature of autopsy   Survival from diagnosis (months)                                            
  --------- --------------- ------------- ------------- -------------------- ------------------- ------- ----------- -------------------------------------------------- --------------------------------- ---------------------------------- ----- ---------------------------------- -----
  A         1               Kidney        69            IV                   4                   2       1           Clear cell carcinoma                               3                                 Sunitinib Temsirolimus             8.5   Multiple lung metastasis\          9.1
                                                                                                                                                                                                                                                   Bone metastasis                    

  2         Lymph node                                                                                                                                                                                                                                                                

  3         Liver                                                                                                                                                                                                                                                                     

  4         Tumor emboli                                                                                                                                                                                                                                                              

  B         5               Kidney        80            III                  3c                  0       0           Clear cell carcinoma                               3                                 Sunitinib                          0.7   IVC tumor emboli                   1.8

  6         Tumor emboli                                                                                                                                                                                                                                                              

  C         7               Mesenterium   62            I                    1b                  0       0           Clear cell carcinoma with spindle cell carcinoma   3                                 Sunitinib Axitinib                 34    Multiple bone metastasis\          43
                                                                                                                                                                                                                                                   Pleural metastasis\                
                                                                                                                                                                                                                                                   Lung metastasis\                   
                                                                                                                                                                                                                                                   Para‐aorta lymph node metastasis   

  8         Lymph node                                                                                                                                                                                                                                                                

  9         Pleura                                                                                                                                                                                                                                                                    

  D         10              Kidney        69            IV                   X                   2       1           Clear cell carcinoma                               3                                 Pazopanib                          2     Multiple lung metastasis\          5.1
                                                                                                                                                                                                                                                   Multiple bone metastasis\          
                                                                                                                                                                                                                                                   Kidney metastasis\                 
                                                                                                                                                                                                                                                   Adrenal metastasis\                
                                                                                                                                                                                                                                                   Pleural metastasis\                
                                                                                                                                                                                                                                                   Skin metastasis                    

  11        Lymph node                                                                                                                                                                                                                                                                

  12        Lymph node                                                                                                                                                                                                                                                                

  13        Adrenal gland                                                                                                                                                                                                                                                             

  14        Skin                                                                                                                                                                                                                                                                      

  15        Pleura                                                                                                                                                                                                                                                                    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ccRCC, clear cell renal cell carcinoma; TKI, tyrosine kinase inhibitor.
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RNA extraction {#cas13331-sec-0004}
--------------

Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s protocol, as described previously.[22](#cas13331-bib-0022){ref-type="ref"}, [25](#cas13331-bib-0025){ref-type="ref"}, [26](#cas13331-bib-0026){ref-type="ref"}, [27](#cas13331-bib-0027){ref-type="ref"}, [28](#cas13331-bib-0028){ref-type="ref"} RNA quality was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).

Quantitative real‐time reverse transcription polymerase chain reaction (qRT‐PCR) {#cas13331-sec-0005}
--------------------------------------------------------------------------------

The procedure for PCR quantification was described previously.[22](#cas13331-bib-0022){ref-type="ref"}, [25](#cas13331-bib-0025){ref-type="ref"}, [26](#cas13331-bib-0026){ref-type="ref"}, [27](#cas13331-bib-0027){ref-type="ref"}, [28](#cas13331-bib-0028){ref-type="ref"} Expression levels of *miR‐10a‐5p* (Assay ID: 000387) were analyzed by TaqMan qRT‐PCR (TaqMan MicroRNA Assay; Applied Biosystems, Foster City, CA, USA) and normalized to the expression of *RNU48* (assay ID: 001006; Applied Biosystems). TaqMan probes and primers for *SKA1* (P/N: Hs00536843_m1; Applied Biosystems), *GAPDH* (internal control; P/N: Hs02758991_m1; Applied Biosystems), and *GUSB* (internal control; P/N: Hs00939627_ml; Applied Biosystems) were assay‐on‐demand gene expression products.

Transfections with mature miRNA, siRNA, or plasmid vectors {#cas13331-sec-0006}
----------------------------------------------------------

The following mature miRNA species were used in this study: mature miRNA and Pre‐miR miRNA Precursor (*hsa‐miR‐10a‐5p*; P/N: AM17100; Applied Biosystems). The following siRNAs were used: Stealth Select RNAi siRNA, si‐*SKA1* (cat. nos. HSS137392 and HSS137393; Invitrogen), and negative control miRNA/siRNA (P/N: AM17111; Applied Biosystems). *SKA1* plasmid vectors were designed and provided by ORIGENE (cat. no. RC202370; Rockville, MD, USA). miRNAs and siRNAs were incubated with Opti‐MEM (Invitrogen) and Lipofectamine RNAiMax transfection reagent (Invitrogen), as previously described.[22](#cas13331-bib-0022){ref-type="ref"}, [25](#cas13331-bib-0025){ref-type="ref"}, [26](#cas13331-bib-0026){ref-type="ref"}, [27](#cas13331-bib-0027){ref-type="ref"}, [28](#cas13331-bib-0028){ref-type="ref"} Plasmid vectors were incubated with Opti‐MEM and Lipofectamine 3000 reagent (Invitrogen) by forward transfection following the manufacturer\'s protocol.

Cell proliferation, migration, and invasion assays {#cas13331-sec-0007}
--------------------------------------------------

786‐O and A498 cells were transfected with 10 nM miRNAs or siRNAs by reverse transfection. Cell proliferation was determined by XTT assays using a Cell Proliferation Kit II (Sigma‐Aldrich, St Louis, MO, USA). Cell migration was evaluated with wound healing assays. Cell invasion was analyzed using modified Boyden chambers containing Transwell‐precoated Matrigel membrane filter inserts (cat. no. 354480; BD Biosciences, Bedford, MA, USA). These assays were carried out as described previously.[22](#cas13331-bib-0022){ref-type="ref"}, [25](#cas13331-bib-0025){ref-type="ref"}, [26](#cas13331-bib-0026){ref-type="ref"}, [27](#cas13331-bib-0027){ref-type="ref"}, [28](#cas13331-bib-0028){ref-type="ref"} All experiments were carried out in triplicate.

Selection of putative target genes regulated by *miR‐10a‐5p* in ccRCC cells {#cas13331-sec-0008}
---------------------------------------------------------------------------

To identify *miR‐10a‐5p* target genes, we used *in silico* analyses and genome‐wide gene expression analyses, as described previously. We used the TargetScanHuman 7.1 (June, 2016 release, <http://www.targetscan.org/vert_71>) database, TCGA, and OncoLnc (<http://www.oncolnc.org/>) to select and narrow down putative miRNA target genes.[29](#cas13331-bib-0029){ref-type="ref"}, [30](#cas13331-bib-0030){ref-type="ref"} An oligo microarray (Human Ge 60K; Agilent Technologies) was used for gene expression analysis. The microarray data were deposited into the GEO database (<https://www.ncbi.nlm.nih.gov/geo/>; accession number: [GSE93290](GSE93290)).

Western blotting {#cas13331-sec-0009}
----------------

Cells were harvested 48 h after transfection, and lysates were prepared. Immunoblotting was carried out with rabbit anti‐SKA1 antibodies (1:1,000 dilution, SAB2701430; Sigma‐Aldrich), anti‐AKT antibody (1:1000, \#4691; Cell Signaling Technology, Danvers, MA, USA), anti‐p‐AKT antibody (1:1000, \#4060; Cell Signaling Technology), anti‐ERK1/2 antibody (1:1000, \#4695; Cell Signaling Technology), anti‐p‐ERK1/2 antibody (1:2000, \#4370; Cell Signaling Technology), anti‐FAK antibody (1:1000, \#3285; Cell Signaling Technology) and anti‐p‐FAK antibody (1:1000, \#8556; Cell Signaling Technology), anti‐SRC antibody (1:1000, \#2123; Cell Signaling Technology) and anti‐p‐SRC antibody (1:1000, \#6943; Cell Signaling Technology). Anti‐glyceraldehyde 3‐phosphate dehydrogenase (GAPDH) antibodies (1:10000, ab8245; Abcam, Cambridge, UK) were used as an internal loading control. Experimental procedures were carried out as described previously.[22](#cas13331-bib-0022){ref-type="ref"}, [25](#cas13331-bib-0025){ref-type="ref"}, [26](#cas13331-bib-0026){ref-type="ref"}, [27](#cas13331-bib-0027){ref-type="ref"}, [28](#cas13331-bib-0028){ref-type="ref"} Protein expression was quantified by using NIH‐ImageJ.

Plasmid construction and dual‐luciferase reporter assays {#cas13331-sec-0010}
--------------------------------------------------------

The partial wild‐type sequence of the *SKA1* 3′‐UTR or that with deletion of the *miR‐10a‐5p* target site was inserted between the *Xho*I‐*Pme*I restriction sites in the 3′‐UTR of the *hRluc* gene in the psiCHECK‐2 vector (C8021; Promega, Madison, WI, USA). The procedures were described previously.[22](#cas13331-bib-0022){ref-type="ref"}, [25](#cas13331-bib-0025){ref-type="ref"}, [26](#cas13331-bib-0026){ref-type="ref"}, [27](#cas13331-bib-0027){ref-type="ref"}, [28](#cas13331-bib-0028){ref-type="ref"}

Immunohistochemistry {#cas13331-sec-0011}
--------------------

Tissue specimens were incubated overnight at 4°C with anti‐SKA1 antibodies (1:500 dilution, SAB2701430; Sigma‐Aldrich). The slides were treated with biotinylated goat antibodies (Histofine SAB‐PO kit; Nichirei, Tokyo, Japan). The procedures were described previously.[22](#cas13331-bib-0022){ref-type="ref"}, [25](#cas13331-bib-0025){ref-type="ref"}, [26](#cas13331-bib-0026){ref-type="ref"}, [27](#cas13331-bib-0027){ref-type="ref"}, [28](#cas13331-bib-0028){ref-type="ref"}

TCGA database analysis of ccRCC {#cas13331-sec-0012}
-------------------------------

To explore the clinical significance of miRNAs and target genes, we used the TCGA database. Gene expression and clinical data were retrieved from cBioportal (<http://www.cbioportal.org/)> [31](#cas13331-bib-0031){ref-type="ref"} and OncoLnc (data downloaded on April 30, 2017). We selected high and low target genes expression groups defined by the median value, and data were analyzed by Kaplan‐Meier survival curves and log‐rank statistics.

Statistical analysis {#cas13331-sec-0013}
--------------------

Relationships between two groups and the numerical values obtained by qRT‐PCR were analyzed using Mann‐Whitney *U*‐tests and paired *t*‐tests. Spearman\'s rank test was used to evaluate the correlation between the expression levels of *miR‐10a‐5p* and *SKA1*. Relationships among more than three variables and numerical values were analyzed using Bonferroni‐adjusted Mann‐Whitney *U*‐tests. Survival analysis was carried out using the Kaplan--Meier method and log‐rank tests with JMP software (version 13; SAS Institute Inc., Cary, NC, USA); all other analyses were carried out using Expert StatView (version 5; SAS Institute Inc.).

Results {#cas13331-sec-0014}
=======

Expression levels of *miR‐10a‐5p* in ccRCC specimens and cell lines {#cas13331-sec-0015}
-------------------------------------------------------------------

The public miRNA database (miRbase: release 21) showed that *miR‐10a‐5p* was located on chromosome 17q21.32. The mature sequence of *miR‐10a‐5p* was found to be 5′‐UACCCUGUAGAUCCGAAUUUGUG‐3′ (Fig. [1](#cas13331-fig-0001){ref-type="fig"}b). We evaluated the expression of *miR‐10a‐5p* in clinical kidney specimens (noncancerous tissues, ccRCC tissues, and autopsy specimens of ccRCC) and cell lines. Expression levels of *miR‐10a‐5p* were significantly downregulated in primary cancer tissues and TKI‐treated tissues compared with those in noncancerous tissues (*P* = 0.0010, *P* = 0.0009, respectively; Fig. [2](#cas13331-fig-0002){ref-type="fig"}a). In 786‐O and A498 cells, expression levels of *miR‐10a‐5p* were relatively low compared with those of clinical specimens (Fig. [2](#cas13331-fig-0002){ref-type="fig"}a).

![Expression levels of *miR‐10a‐5p* in clear cell renal cell carcinoma (ccRCC) clinical specimens and functional significance of *miR‐10a‐5p* in ccRCC cells. (a) Expression levels of *miR‐10a‐5p* in ccRCC clinical specimens and cell lines determined using qRT‐PCR. *RNU48* was used as an internal control. TKI, tyrosine kinase inhibitor. (b) Cell proliferation was determined by XTT assays 72 h after transfection with 10 nM *miR‐10a‐5p*. \**P* \< 0.0001, \*\**P* \< 0.01. (c) Cell migration activity was assessed by wound‐healing assays 48 h after transfection with 10 nM *miR‐10a‐5p*. \**P* \< 0.0001. (d) Cell invasion activity was characterized by invasion assays 48 h after transfection with 10 nM *miR‐10a‐5p*. \**P* \< 0.0001.](CAS-108-2088-g002){#cas13331-fig-0002}

Effects of restoring *miR‐10a‐5p* on cell proliferation, migration, and invasion activities in ccRCC cell lines {#cas13331-sec-0016}
---------------------------------------------------------------------------------------------------------------

To investigate the functional efficacy of *miR‐10a‐5p*, we carried out gain‐of‐function studies using miRNA transfection into 786‐O and A498 cells. XTT assays showed that cell proliferation was significantly inhibited in *miR‐10a‐5p* transfectants compared with that in mock or miR‐control transfectants (Figs [2](#cas13331-fig-0002){ref-type="fig"}b; [S1](#cas13331-sup-0001){ref-type="supplementary-material"}a). Migration assays showed that cell migration activity was significantly inhibited in *miR‐10a‐5p* transfectants in comparison with those in mock or miR‐control transfectants (Figs [2](#cas13331-fig-0002){ref-type="fig"}c; [S2](#cas13331-sup-0002){ref-type="supplementary-material"}a). Similarly, Matrigel invasion assays showed that cell invasion activity was significantly inhibited in *miR‐10a‐5p* transfectants in comparison with those in mock or miR‐control transfectants (Figs [2](#cas13331-fig-0002){ref-type="fig"}d; [S2](#cas13331-sup-0002){ref-type="supplementary-material"}b).

Identification of candidate genes regulated by *miR‐10a‐5p* in ccRCC cells {#cas13331-sec-0017}
--------------------------------------------------------------------------

To further elucidate the molecular mechanisms and pathways regulated by antitumor *miR‐10a‐5p* in ccRCC cells, we carried out a combination of *in silico* analyses and oligo microarray analyses using *miR‐10a‐5p* transfectants. The strategy for selection of *miR‐10a‐5p* target genes is shown in Figure [3](#cas13331-fig-0003){ref-type="fig"}. First, we used TargetScanHuman 7.1 database and identified that 3661 genes had putative target sites for *miR‐10a‐5p* in their 3′‐UTR. Next, we paired down the 3661 genes based on gene expression data (GEO database accession number: [GSE93290](GSE93290)), and 31 genes were markedly downregulated after transfection of 786‐O and A498 cells with *miR‐10a‐5p* (fold‐change log~2~ \< −2.0; Table[3](#cas13331-tbl-0003){ref-type="table-wrap"}). Finally, we checked the expression status of these 31 genes and the clinical significance of ccRCC using the OncoLnc database (<http://www.oncolnc.org/>). Kaplan‐Meier survival curves showed that high expression of eight genes was associated with poor prognosis in ccRCC (Table[3](#cas13331-tbl-0003){ref-type="table-wrap"}; Figs [4](#cas13331-fig-0004){ref-type="fig"}a, [5](#cas13331-fig-0005){ref-type="fig"}). Among these genes, we focused on *SKA1*, which was most downregulated by transfection of *miR‐10a‐5p*, and showed the most dramatic difference in OncoLnc prognostic analysis (*P* = 2.72E−08, Fig. [4](#cas13331-fig-0004){ref-type="fig"}a).

![Identification of *miR‐10a‐5p* target genes. Flow chart of the strategy for identification of *miR‐10a‐5p* target genes.](CAS-108-2088-g003){#cas13331-fig-0003}

###### 

Candidate target genes regulated by miR‐10a‐5p in clear cell renal cell carcinoma (ccRCC)

  Gene Symbol   Gene name                                                                                             Location   No. conserved sites   No. poorly conserved sites   Log~2~ ratio (A498)   Log~2~ ratio (786‐O)   Log~2~ ratio (average)   TCGA‐KIRC OncoLnc 25:25 *P*‐value
  ------------- ----------------------------------------------------------------------------------------------------- ---------- --------------------- ---------------------------- --------------------- ---------------------- ------------------------ -------------------------------------------------
  *SKA1*        Spindle and kinetochore‐associated protein 1                                                          18q21.1    0                     1                            −5.06                 −2.01                  −3.54                    [a](#cas13331-note-0004){ref-type="fn"}2.72E−08
  *SLC7A1*      Solute carrier family 7 (cationic amino acid transporter, y+ system), member 1                        13q12.3    0                     1                            −3.38                 −2.23                  −2.81                    2.62E−01
  *SUMF1*       Sulfatase modifying factor 1                                                                          3p26.1     0                     1                            −2.35                 −2.65                  −2.50                    9.42E−01
  *P4HB*        Prolyl 4‐hydroxylase, beta polypeptide                                                                17q25.3    0                     1                            −2.61                 −2.35                  −2.48                    [a](#cas13331-note-0004){ref-type="fn"}2.75E−04
  *USP46*       Ubiquitin specific peptidase 46                                                                       4q12       1                     1                            −1.96                 −2.9                   −2.43                    6.62E−02
  *ELOVL2*      ELOVL fatty acid elongase 2                                                                           6p24.2     1                     0                            −2.25                 −2.39                  −2.32                    [a](#cas13331-note-0004){ref-type="fn"}6.39E−04
  *KCTD13*      Potassium channel tetramerization domain containing 13                                                16p11.2    0                     1                            −2.69                 −1.72                  −2.21                    [a](#cas13331-note-0004){ref-type="fn"}4.00E−06
  *LINC00908*   Long intergenic non‐protein coding RNA 908                                                            18q23      0                     1                            −2.62                 −1.79                  −2.21                    1.52E−01
  *SUN2*        Sad1 and UNC84 domain containing 2                                                                    22q13.1    0                     3                            −2.10                 −2.31                  −2.21                    1.31E−01
  *FCF1*        FCF1 rRNA‐processing protein                                                                          14q24.3    0                     1                            −2.51                 −1.84                  −2.18                    8.74E−04
  *ARG2*        Arginase 2                                                                                            14q24.1    0                     1                            −2.06                 −2.25                  −2.16                    6.91E−01
  *SLAMF7*      SLAM family member 7                                                                                  1q23.3     0                     1                            −1.52                 −2.77                  −2.15                    1.23E−01
  *PRKAA2*      Protein kinase, AMP‐activated, alpha 2 catalytic subunit                                              1p32.2     1                     3                            −1.66                 −2.58                  −2.12                    2.10E−09
  *FANCC*       Fanconi anemia, complementation group C                                                               9q22.32    0                     3                            −2.23                 −2.00                  −2.12                    4.29E−03
  *PDCL*        Phosducin‐like                                                                                        9q33.2     0                     1                            −2.03                 −2.03                  −2.03                    1.19E−03
  *PSIP1*       PC4 and SFRS1 interacting protein 1                                                                   9p22.3     0                     1                            −2.51                 −1.53                  −2.02                    4.96E−02
  *CD3D*        CD3d molecule, delta (CD3‐TCR complex)                                                                11q23.3    0                     2                            −2.20                 −1.82                  −2.01                    9.89E−02
  *C1QL4*       Complement component 1, q subcomponent‐like 4                                                         12q13.12   0                     1                            −1.97                 −2.04                  −2.01                    7.02E−03
  *SDC1*        syndecan 1                                                                                            2p24.1     1                     0                            −1.94                 −2.05                  −2.00                    6.76E−01
  *DNAL4*       Dynein, axonemal, light chain 4                                                                       22q13.1    0                     1                            −1.91                 −2.06                  −1.99                    7.34E−01
  *NUP62CL*     Nucleoporin 62kDa C‐terminal like                                                                     Xq22.3     0                     2                            −1.7                  −2.03                  −1.87                    4.12E−02
  *MTUS1*       Microtubule associated tumor suppressor 1                                                             8p22       0                     1                            −1.93                 −1.76                  −1.85                    4.03E−03
  *RTN4R*       Reticulon 4 receptor                                                                                  22q11.21   0                     1                            −2.07                 −1.6                   −1.84                    [a](#cas13331-note-0004){ref-type="fn"}1.24E−05
  *PM20D2*      Peptidase M20 domain containing 2                                                                     6q15       0                     1                            −2.04                 −1.56                  −1.80                    2.92E−02
  *PCBD1*       Pterin‐4 alpha‐carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor 1 alpha   10q22.1    0                     1                            −1.55                 −2.03                  −1.79                    4.00E−01
  *APAF1*       Apoptotic peptidase activating factor 1                                                               12q23.1    0                     3                            −1.90                 −1.63                  −1.77                    [a](#cas13331-note-0004){ref-type="fn"}1.18E−03
  *DOHH*        Deoxyhypusine hydroxylase/monooxygenase                                                               19p13.3    0                     2                            −1.78                 −1.56                  −1.67                    [a](#cas13331-note-0004){ref-type="fn"}6.16E−03
  *AIM1*        Absent in melanoma 1                                                                                  6q21       0                     1                            −1.71                 −1.55                  −1.63                    2.67E−01
  *ANXA7*       Annexin A7                                                                                            10q22.2    1                     0                            −1.50                 −1.65                  −1.58                    5.17E−02
  *HS3ST1*      Heparan sulfate (glucosamine) 3‐O‐sulfotransferase 1                                                  4p15.33    0                     1                            −1.54                 −1.56                  −1.55                    2.99E−03
  *IMPAD1*      Inositol monophosphatase domain containing 1                                                          8q12.1     0                     1                            −1.52                 −1.56                  −1.54                    [a](#cas13331-note-0004){ref-type="fn"}5.59E−03

Kaplan--Meier survival analysis *P* \< 0.05. Poor prognosis with high expression in

ccRCC.

John Wiley & Sons, Ltd

![Kaplan‐Meier survival curves based on *SKA1* expression in patients with clear cell renal cell carcinoma (ccRCC), and expression levels of *SKA1* in ccRCC clinical specimens. (a) Kaplan‐Meier survival curve for overall survival rate based on *SKA1* expression in patients with ccRCC. (b) Expression levels of *SKA1* in ccRCC clinical specimens and cell lines. *GUSB* was used as an internal control. TKI, tyrosine kinase inhibitor. (c) Negative correlation between *miR‐10a‐5p* and *SKA1*.](CAS-108-2088-g004){#cas13331-fig-0004}

![Kaplan‐Meier survival curves for overall survival rates based on expression of seven genes, excluding *SKA1*, in patients with clear cell renal cell carcinoma (ccRCC).](CAS-108-2088-g005){#cas13331-fig-0005}

Expression of SKA1 in ccRCC clinical specimens {#cas13331-sec-0018}
----------------------------------------------

A total of 15 pairs of primary ccRCC specimens, adjacent noncancerous specimens, and TKI‐treatment failure autopsy specimens from 15 sites were used for the expression analysis of *SKA1* by qRT‐PCR. Expression of *SKA1* was significantly upregulated in primary cancer tissues compared with that in normal tissues (*P* = 0.0011; Fig. [4](#cas13331-fig-0004){ref-type="fig"}b) and was significantly higher in autopsy specimens than in primary cancer tissues (*P* = 0.0011; Fig. [4](#cas13331-fig-0004){ref-type="fig"}b). Additionally, Spearman\'s rank test indicated a negative correlation between the expression levels of *miR‐10a‐5p* and *SKA1* (Fig. [4](#cas13331-fig-0004){ref-type="fig"}c).

Furthermore, to analyze SKA1 protein expression, immunohistochemistry was carried out with a ccRCC tissue microarray (cat. no. KD806; US Biomax, Rockville, MD, USA) and autopsy specimens after TKI treatment (Patient D, Table[2](#cas13331-tbl-0002){ref-type="table-wrap"}). Patient characteristics for samples used in the tissue microarray are as described in <http://www.biomax.us/tissue-arrays/Kidney/KD806>. SKA1 was strongly expressed in primary ccRCC tissues and autopsy specimens after TKI treatment compared with that in normal kidney (Fig.[6](#cas13331-fig-0006){ref-type="fig"}).

![Expression of SKA1 in clinical clear cell renal cell carcinoma (ccRCC) specimens using a tissue microarray and autopsy tissues. Representative immunohistochemical staining for SKA1 in a ccRCC tissue microarray (cat. no. KD806; US Biomax, Inc., Rockville, MD,USA) and autopsy specimens after tyrosine kinase inhibitor (TKI) treatment (Patient D, Table [2](#cas13331-tbl-0002){ref-type="table-wrap"}). SKA1 was strongly expressed in ccRCC tissues. (a) Normal kidney. (b) ccRCC tissues. (c) ccRCC autopsy tissues after TKI treatment.](CAS-108-2088-g006){#cas13331-fig-0006}

*SKA1* was directly regulated by *miR‐10a‐5p* transfection in ccRCC cells {#cas13331-sec-0019}
-------------------------------------------------------------------------

We carried out qRT‐PCR and western blotting to validate whether restoration of *miR‐10a‐5p* in 786‐O and A498 cells reduced the expression of SKA1. Expression of *SKA1* mRNA was significantly suppressed by *miR‐10a‐5p* transfection compared with that in mock‐ or miR‐control‐transfected cells (Fig. [7](#cas13331-fig-0007){ref-type="fig"}a). Similarly, SKA1 protein expression was repressed in the *miR‐10a‐5p* transfectants (Fig. [7](#cas13331-fig-0007){ref-type="fig"}b).

![Direct regulation of *SKA1* by *miR‐10a‐5p* in clear cell renal cell carcinoma (ccRCC) cells. (a) *SKA1* mRNA expression was evaluated using qRT‐PCR in 786‐O and A498 cells 48 h after transfection with *miR‐10a‐5p*. *GAPDH* was used as an internal control. \**P* \< 0.0001. (b) SKA1 protein expression was evaluated by western blotting in 786‐O and A498 cells 72 h after transfection with *miR‐10a‐5p*. GAPDH was used as a loading control. (c) *miR‐10a‐5p* binding site in the 3′‐UTR of *SKA1* mRNA. Dual luciferase reporter assays in 786‐O using vectors encoding the putative *miR‐10a‐5p* target site of *SKA1* 3′‐UTR (positions 28‐35). Data were normalized by expression ratios of *Renilla*/firefly luciferase activities. \**P* \< 0.0001.](CAS-108-2088-g007){#cas13331-fig-0007}

Next, we carried out luciferase reporter assays to determine whether *SKA1* mRNA had a functional target site. The TargetScan database predicted that *miR‐10a‐5p* bound at position 28--35 in the 3′‐UTR of *SKA1*. We used vectors encoding a partial wild‐type sequence of the 3′‐UTR of *SKA1* mRNA, including the predicted *miR‐10a‐5p* target site, or a vector lacking the *miR‐10a‐5p* target site. Luminescence intensity was significantly reduced by cotransfection with *miR‐10a‐5p* and the vector carrying the wild‐type 3′‐UTR of *SKA1*. However, luminescence intensity was not suppressed when the target site of *miR‐10a‐5p* was deleted from the vectors (Fig. [7](#cas13331-fig-0007){ref-type="fig"}c).

Effects of silencing *SKA1* in ccRCC cell lines {#cas13331-sec-0020}
-----------------------------------------------

To examine the functional significance of *SKA1*, we carried out loss‐of‐function studies using si‐*SKA1* transfectants. First, we evaluated the knockdown efficiency of si‐*SKA1* transfection in 786‐O and A498 cells. In this study, we used two types of si‐*SKA1* (si‐*SKA1*‐1 and si‐*SKA1*‐2). qRT‐PCR and western blotting analyses showed that transfection with both siRNAs effectively downregulated *SKA1* mRNA and SKA1 protein expression in 786‐O and A498 cells (Fig. [8](#cas13331-fig-0008){ref-type="fig"}a,b). Furthermore, functional assays indicated that si‐*SKA1* transfection markedly inhibited cell proliferation, migration, and invasion in comparison with mock‐ or si‐control‐transfected cells (Figs [8](#cas13331-fig-0008){ref-type="fig"}c; [S1](#cas13331-sup-0001){ref-type="supplementary-material"}b, [S3](#cas13331-sup-0003){ref-type="supplementary-material"}a, [S4](#cas13331-sup-0004){ref-type="supplementary-material"}a).

![Effects of *SKA1* silencing on clear cell renal cell carcinoma (ccRCC) cell lines. (a) *SKA1* mRNA expression was evaluated using qRT‐PCR analysis of 786‐O and A498 cells 48 h after transfection with si*‐SKA1*‐1 or si*‐SKA1*‐2. *GAPDH* was used as an internal control. \**P* \< 0.0001. (b) SKA1 protein expression was evaluated by western blotting analysis of 786‐O and A498 cells 72 h after transfection with *miR‐10a‐5p*. GAPDH was used as a loading control. (c) Cell proliferation was determined using XTT assays 72 h after transfection with 10 nM si*‐SKA1*‐1 or si*‐SKA1*‐2. \**P* \< 0.0001. (d) Cell migration activity was assessed by wound‐healing assays 48 h after transfection with 10 nM *si‐SKA1*‐1 or *si‐SKA1*‐2. \**P* \< 0.0001. (e) Cell invasion activity was characterized by invasion assays 48 h after transfection with 10 nM *si‐SKA1*‐1 or *si‐SKA1*‐2. \**P* \< 0.0001.](CAS-108-2088-g008){#cas13331-fig-0008}

Effects of cotransfection of *SKA1/miR‐10a‐5p* in 786‐O cells {#cas13331-sec-0021}
-------------------------------------------------------------

To validate whether the molecular pathway of *SKA1/miR‐10a‐5p* was critical for the progression of ccRCC, we carried out *SKA1* rescue experiments by cotransfection with *SKA1* and *miR‐10a‐5p* in 786‐O cells. SKA1 protein expression by Western blotting analysis is shown in Figure [9](#cas13331-fig-0009){ref-type="fig"}a. Functional assays showed that the migration and invasion abilities of ccRCC cells were recovered by *SKA1* and *miR‐10a‐5p* transfection compared with cells with restored *miR‐10a‐5p* only (Figs [9](#cas13331-fig-0009){ref-type="fig"}b--d; [S1](#cas13331-sup-0001){ref-type="supplementary-material"}c, [S5](#cas13331-sup-0005){ref-type="supplementary-material"}a,b). These results supported that *SKA1* affected the aggressiveness of ccRCC cells.

![Effects of cotransfection of *SKA1/miR‐10a‐5p* in 786‐O cells. (a) SKA1 protein expression was evaluated by western blotting analysis of 786‐O cells 72 h after reverse transfection with *miR‐10a‐5p* and 48 h after forward transfection with the *SKA1* vector. GAPDH was used as a loading control. (b) Cell proliferation was determined using XTT assays 72 h after reverse transfection with *miR‐10a‐5p* and 48 h after forward transfection with the *SKA1* vector. \*\**P* \< 0.01. (c) Cell migration activity was assessed by wound‐healing assays 48 h after reverse transfection with *miR‐10a‐5p* and 24 h after forward transfection with the *SKA1* vector. \**P* \< 0.0001. (d) Cell invasion activity was characterized by invasion assays 48 h after reverse transfection with *miR‐10a‐5p* and 48 h after forward transfection with *SKA1* vector. \**P* \< 0.0001.](CAS-108-2088-g009){#cas13331-fig-0009}

Clinical significance of *SKA1* in ccRCC {#cas13331-sec-0022}
----------------------------------------

To explore the clinical significance of *SKA1* in ccRCC, we analyzed Kaplan‐Meier curves of DFS rates according to the expression level of *SKA1*, and the relationships among *SKA1* expression and cancer stage, tumor stage, and histological grade in ccRCC were evaluated using the TCGA‐KIRC database. Kaplan‐Meier curves for DFS rates showed that the DFS of the high *SKA1* expression group was significantly shorter than that of the low expression group in ccRCC (*P* \< 0.0001, Fig. [10](#cas13331-fig-0010){ref-type="fig"}a). Additionally, expression levels of *SKA1* were significantly increased in cases of advanced disease stage, advanced T stage, and advanced histological grade (Fig. [10](#cas13331-fig-0010){ref-type="fig"}b--d). These analyses suggested that *SKA1* affected disease progression and malignancy in ccRCC. Similarly, TCGA data analysis results of clinical significance for the other seven genes are shown in Figures [S6--S9](#cas13331-sup-0006){ref-type="supplementary-material"}.

![Kaplan‐Meier survival curve based on *SKA1* expression in patients with clear cell renal cell carcinoma (ccRCC), and expression levels of *SKA1* according to TNM stage, T stage, and histological grade. (a) Kaplan‐Meier survival curves for disease‐free survival rate based on *SKA1* expression in patients with ccRCC. (b‐d) Expression levels of *SKA1* were significantly increased in cases of advanced TNM stage, advanced T stage, and advanced histological grade. \**P* \< 0.01, \*\**P* \< 0.001, \*\*\**P* \< 0.0001.](CAS-108-2088-g010){#cas13331-fig-0010}

Effects of *SKA1* downstream signaling by si‐*SKA1* knockdown or *miR‐10a‐5p* restoration in RCC cells {#cas13331-sec-0023}
------------------------------------------------------------------------------------------------------

We investigated the downstream signals of *miR‐10a‐5p*/*SKA1* axis in 786‐O cells using mature *miR‐10a‐5p* or si‐*SKA1* transfectants. To explore the downstream survival pathways of *miR‐10a‐5p*/*SKA1* axis, phosphorylation of ERK1/2 (Thr 202/Tyr 204), AKT (Ser 473), FAK (Tyr 397) and SRC (Tyr 416) was examined. Knockdown of *SKA1* or restoration of *miR‐10a‐5p* markedly reduced the phosphorylation of ERK1/2, AKT, FAK and SRC (Fig. [11](#cas13331-fig-0011){ref-type="fig"}).

![Effects of the gene encoding SKA1 protein on downstream signaling. Knockdown of *SKA1* and restoration of *miR‐10a‐5p* in 786‐O cells reduced the phosphorylation of ERK1/2, AKT,FAK and SRC. GAPDH was used as a loading control.](CAS-108-2088-g011){#cas13331-fig-0011}

Discussion {#cas13331-sec-0024}
==========

Based on the underlying molecular oncogenic mechanisms of RCC, several molecular targeted agents have been developed to improve the prognosis of patients with advanced RCC.[10](#cas13331-bib-0010){ref-type="ref"}, [11](#cas13331-bib-0011){ref-type="ref"} However, although almost all patients with RCC respond to initial treatment with molecular targeted therapies, cancer cells ultimately become resistant to these treatments.[12](#cas13331-bib-0012){ref-type="ref"}, [32](#cas13331-bib-0032){ref-type="ref"}, [33](#cas13331-bib-0033){ref-type="ref"} Several molecular mechanisms of drug resistance have been reported in RCC; however, all of these mechanisms are not sufficient to explain the observed changes in cancer cells. Understanding these molecular mechanisms using current genomic approaches is the first step to overcoming drug resistance in RCC cells.

To investigate the molecular mechanisms of drug resistance in RCC cells, we constructed a miRNA expression signature using autopsy specimens from patients with ccRCC who exhibited TKI‐treatment failure.[22](#cas13331-bib-0022){ref-type="ref"} Our present data demonstrated that *miR‐10a‐5p* acted as an antitumor miRNA in RCC cells. TCGA database analyses indicated that downregulation of *miR‐10a‐5p* was associated with poor prognosis in patients with RCC. *miR‐10a* belongs to the *miR‐10* family together with *miR‐10b*, and *miR‐10a‐5p* is a guide strand of *miR‐10a*. Previous studies have indicated that *miR‐10a* is deregulated in several types of cancers. [34](#cas13331-bib-0034){ref-type="ref"}, [35](#cas13331-bib-0035){ref-type="ref"}, [36](#cas13331-bib-0036){ref-type="ref"}, [37](#cas13331-bib-0037){ref-type="ref"} In different types of cancer, *miR‐10a* has dual functions as either a cancer‐promoting or cancer‐suppressing miRNA. In RCC, a recent study showed that *miR‐10a‐5p* is a predictor of progression and survival for RCC;[38](#cas13331-bib-0038){ref-type="ref"} however, the functional significance and relevant molecular mechanisms of *miR‐10a‐5p* in cancer progression are still unknown.

One of the main challenges in miRNA studies is identification of miRNA‐target genes and RNA networks mediated by antitumor miRNAs in cancer cells. A total of 31 genes were identified as putative targets of *miR‐10a‐5p* regulation in ccRCC cells in this study. Among them, eight genes (*SKA1*,*P4HB*,*ELOVL2*,*KCTD13*,*RTN4R*,*APAF1*,*ANXA7*, and *IMPAD1*) were associated with poor prognosis in patients with RCC by TCGA analyses. We focused on the *SKA1* gene because overexpression of this gene showed the most significant association with poor prognosis in RCC. Another seven genes may also be involved in the pathology of RCC. Analyses of these genes are important for elucidating the molecular mechanisms of RCC oncogenesis, metastasis and drug resistance.

It is well known that one mRNA was regulated by a number of miRNAs. TargetScan database searching showed that *SKA1* was a putative target for *miR‐10b‐5p*,*miR‐24‐3p* and *miR‐23b‐3p* which were significantly downregulated in our miRNA signature of TKI treatment of RCC specimens.[22](#cas13331-bib-0022){ref-type="ref"} Our previous studies demonstrated that *miR‐24‐3p* and *miR‐23b‐3p* acted as antitumor miRNAs targeting several oncogenic genes.[39](#cas13331-bib-0039){ref-type="ref"}, [40](#cas13331-bib-0040){ref-type="ref"} Also, *miR‐10b‐5p* functioned as an antitumor miRNA in several types of cancers including RCC.[41](#cas13331-bib-0041){ref-type="ref"}, [42](#cas13331-bib-0042){ref-type="ref"}, [43](#cas13331-bib-0043){ref-type="ref"} We made the following hypothesis from these findings, *SKA1* is regulated by several antitumor miRNAs which contribute to RCC pathogenesis and drug resistance. From the analyses of these miRNAs, it can be expected to lead to elucidation of the mechanism of drug resistance of RCC.

Several studies have indicated that *SKA1* is involved in the growth and proliferation of various types of cancer, including oral adenosquamous and hepatocellular carcinoma, bladder cancer, gastric cancer, prostate cancer, thyroid cancer, non‐small cell lung cancer, and glioblastoma.[44](#cas13331-bib-0044){ref-type="ref"}, [45](#cas13331-bib-0045){ref-type="ref"}, [46](#cas13331-bib-0046){ref-type="ref"}, [47](#cas13331-bib-0047){ref-type="ref"}, [48](#cas13331-bib-0048){ref-type="ref"}, [49](#cas13331-bib-0049){ref-type="ref"}, [50](#cas13331-bib-0050){ref-type="ref"}, [51](#cas13331-bib-0051){ref-type="ref"} In the human genome, *SKA1*,*SKA2*, and *SKA3* form the SKA complex. During mitosis, the SKA complex is localized between the outer kinetochore interface and the spindle microtubules. This complex is indispensable for stabilizing adhesion of spindle microtubules to kinetochores and maintaining the metaphase plate; therefore, this complex is critical for appropriate chromosome segregation during mitosis.[52](#cas13331-bib-0052){ref-type="ref"}, [53](#cas13331-bib-0053){ref-type="ref"}, [54](#cas13331-bib-0054){ref-type="ref"} Interestingly, the expression of *SKA1* contributes to cisplatin resistance in lung cancer cells by protecting the cells from cisplatin‐induced apoptosis.[50](#cas13331-bib-0050){ref-type="ref"} Knockdown of *SKA1* decreases the activation of extracellular signal‐regulated kinase (ERK1/2) and AKT‐mediated signaling pathways in lung cancer cells.[50](#cas13331-bib-0050){ref-type="ref"} Another study also demonstrated that knockdown of *SKA1* alleviated the activation of ERK1/2 and AKT in bladder cancer cells.[46](#cas13331-bib-0046){ref-type="ref"} In adenoid cystic carcinoma, knockdown of *SKA1* inhibited cell proliferation, invasion, and migration, and cell cycle arrest by regulating cell cycle‐promoting genes and the matrix metalloproteinase‐9 gene.[55](#cas13331-bib-0055){ref-type="ref"} These findings suggested that the expression of *SKA1* may be induced by cancer‐promoting genes and could contribute to cancer cell aggressiveness and drug resistance. Many reports have demonstrated that acquired resistance of RCC cells to molecular targeted therapies induces cancer‐promoting genes and activates several alternative pathways.[12](#cas13331-bib-0012){ref-type="ref"}, [56](#cas13331-bib-0056){ref-type="ref"}, [57](#cas13331-bib-0057){ref-type="ref"} A previous study showed that sunitinib treatment significantly suppressed phosphorylation of ERK1/2 and AKT in TKI‐sensitive RCC cells, whereas inhibition of phosphorylation was not observed in TKI‐resistant RCC cells.[58](#cas13331-bib-0058){ref-type="ref"} In this study, phosphorylation of ERK1/2 and AKT was suppressed by knockdown of *SKA1* and restoration of *miR‐10a‐5p*. This suggests that downregulation of *miR‐10a‐5p* and overexpression of the *SKA1* axis may be involved in resistance to VEGF‐ and mTOR‐targeted treatments in RCC.

In conclusion, downregulation of *miR‐10a‐5p* was detected in the miRNA signature of TKI‐failure RCC and acted as an antitumor miRNA in RCC cells. To the best of our knowledge, this is the first study showing that antitumor *miR‐10a‐5p* directly regulated *SKA1* in RCC cells. Overexpression of SKA1 was observed in primary and TKI‐failure RCC specimens. Moreover, downregulation of *miR‐10a‐5p* and overexpression of *SKA1* were associated with poor prognosis in patients with RCC. Elucidation of *miR‐10a‐5p/SKA1*‐mediated molecular networks may improve our understanding of the pathogenesis of primary RCC and molecular targeted treatment failure in RCC and facilitate the development of new treatment strategies.
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**Fig. S1.** Proliferation curves over time according to the results of XTT assays. (a) Transfection with *miR‐10a‐5p* in 786‐O and A498 cells. (b) Transfection of si‐*SKA1* into 786‐O and A498 cells. (c) SKA1 rescue experiments. \**P* \< 0.001, \*\**P* \< 0.0001.
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Click here for additional data file.

###### 

**Fig. S2.** Phase micrographs of wound healing and invasion assays by transfection with *miR‐10a‐5p* in RCC cell lines. (a) Phase micrographs of 786‐O and A498 cells 14 h after monolayer wound healing. (b) Phase micrographs of invading 786‐O and A498 cells.
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Click here for additional data file.

###### 

**Fig. S3.** Phase micrographs of wound healing and invasion assays by transfection with si‐*SKA1* in 786‐O cells. (a) Phase micrographs of 786‐O cells 14 h after monolayer wound healing. (b) Phase micrographs of invading 786‐O cells.
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Click here for additional data file.

###### 

**Fig. S4.** Phase micrographs of wound healing and invasion assays by transfection with si‐*SKA1* in A498 cells. (a) Phase micrographs of A498 cells 14 h after monolayer wound healing. (b) Phase micrographs of invading A498 cells.
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Click here for additional data file.

###### 

**Fig. S5.** Phase micrographs of wound healing and invasion assays by cotransfection with *SKA1/miR‐10a‐5p* in 786‐O cells. (a) Phase micrographs of 786‐O cells 14 h after monolayer wound healing. (b) Phase micrographs of invading 786‐O cells.
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Click here for additional data file.

###### 

**Fig. S6.** Kaplan‐Meier survival curves for disease‐free survival rates based on expression of seven genes, excluding *SKA1*, in patients with ccRCC.
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Click here for additional data file.

###### 

**Figs S7--9.** Expression levels of seven genes, excluding *SKA1*, according to TNM stage, T stage, and histological grade in patients with ccRCC from TCGA database. \**P* \< 0.01, \*\**P* \< 0.001, \*\*\**P* \< 0.0001.
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